Skip to main content
. 2020 Dec 1;202(11):1509–1519. doi: 10.1164/rccm.202005-1885OC

Table 1.

Characteristics of Patients with COVID-19 (n = 38) and Non–COVID-19 (n = 36) ARDS

Variables Available Data COVID-19 ARDS (n = 38) Non–COVID-19 ARDS (n = 36) P Value
Demographics and comorbidities        
 Age 74 63 (50–72) 58 (44–70) 0.443
 Sex, M 74 32 (84) 28 (78) 0.480
 BMI, kg/cm2 73 27.9 (25.6–32.7) 26.7 (22.6–31.0) 0.117
 Obesity 74 13 (36) 5 (14) 0.029
 Diabetes mellitus 74 12 (32) 7 (19) 0.232
 COPD 74 5 (13) 7 (19) 0.463
 Chronic heart failure 74 6 (16) 7 (19) 0.680
 Liver cirrhosis 74 0 (0) 2 (6) 0.141
 Sickle cell disease 74 1 (3) 4 (11) 0.143
 End-stage renal disease 74 1 (3) 0 (0) 0.327
 Smoker 74 15 (39) 16 (44) 0.665
Patients’ characteristics upon ICU admission        
 First symptom to admission*, d 74 6 (3–8) 3 (0–7) 0.007
 SOFA 74 9 (6–10) 9 (6–11) 0.483
 SAPS II 74 38 (32–45) 39 (31–54) 0.808
 Invasive mechanical ventilation 74 25 (66) 20 (56) 0.476
 Temperature 72 38.0 (38.0–40.0) 38.6 (37.8–39.6) 0.634
 ARDS severity (Berlin) 74     0.007
  Mild 9 (24) 1 (3)
  Moderate 18 (47) 14 (39)
  Severe 11 (29) 21 (58)
 PaO2/FiO2 ratio, mm Hg 74 125 (94–169) 94 (72–129) 0.025
 PaCO2, mm Hg 74 40 (37–48) 45 (38–51) 0.168
 pH 74 7.42 (7.32–7.45) 7.36 (7.27–7.42) 0.039
 Left ventricle ejection fraction, % 74 61 (52–70) 60 (50–60) 0.030
 Arterial blood lactates, mM 74 1.4 (1.2–1.9) 1.4 (0.8–2.2) 0.695
 Creatinine, μmol/L 74 82 (66–120) 87 (65–144) 0.455
 Alanine aminotransferase, IU/L 74 36 (22–47) 45 (24–100) 0.137
 Aspartate aminotransferase, IU/L 74 51 (41–85) 62 (29–145) 0.552
 Bilirubin, μmol/L 74 9 (7–11) 14 (8–21) 0.013
 Prothrombin time, % 74 80 (72–87) 77 (61–87) 0.222
 WBC counts, 103/mm3 74 7.3 (5.6–9.8) 12.8 (8.3–19.0) <0.001
 Lymphocytes, 103/mm3 73 0.6 (0.5–0.9) 0.9 (0.6–1.2) 0.035
 Monocytes, 103/mm3 73 0.3 (0.2–0.4) 0.7 (0.2–1.2) 0.008
 Neutrophils, 103/mm3 73 6.4 (4.2–8.6) 10.5 (7.2–16.2) <0.001
 Neutrophils-to-lymphocytes ratio 73 8.8 (5.5–15.2) 11.1 (8.3–18.7) 0.167
 Neuromuscular blockers 74 24 (63) 30 (83) 0.051
 Prone position 74 13 (34) 13 (36) 0.864
 Nitric oxide 74 0 (0) 2 (6) 0.141
 ECMO 74 0 (0) 2 (6) 0.141
 Vasopressor support 74 22 (58) 25 (69) 0.302
Microbiological documentation (other than SARS-CoV-2) 74 9 (24) 24 (67) 0.0002
 Bacteria        
  Gram positive
   Staphylococcus aureus 1 1
   Streptococcus pneumoniae 0 5
   Group A Streptococcus 0 2
  Gram negative    
   Enterobacteriaceae 3 7
   Nonfermenting bacteria 2 1
   Haemophilus influenzae 0 2
  Intracellular pathogens    
   Legionella pneumophila 0 4
   Mycoplasma pneumonia 0 2
 Virus (other than SARS-CoV-2)   2 (5) 11 (30) 0.005
  Influenza 0 6
  Rhinovirus 2 1
  Others 0 4§

Definition of abbreviations: ARDS = acute respiratory distress syndrome; BMI = body mass index; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease; ECMO = extracorporeal membrane oxygenation; SOFA = Sequential Organ Failure Assessment; SAPS II = Simplified Acute Physiology Score II; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; WBC = white blood cell.

Continuous variables are presented as median (first–third quartiles); P values come from the Mann-Whitney test. Categorical variables are shown as n (%); P values come from the chi-square or the Fisher exact test, as appropriate. Bold results are statistically significant at the P < 0.05 level.

*

Time lag between the first symptoms of the disease and ICU admission.

Including three patients who had bacterial coinfections (group A Streptococcus, Streptococcus pneumoniae, and Enterobacter cloacae).

Influenza A(H1N1)pdm2009 (n = 4) and influenza B (n = 2).

§

Seasonal coronavirus (n = 1), adenovirus (n = 1), metapneumovirus (n = 1), and respiratory syncytial virus (n = 1).